Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High - Here's Why

Key Points

• Halozyme Therapeutics reached a new 52-week high of $109.68, trading recently at $108.08. Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating, although the average price target of $91.20 is below the current share price.
• The company reported strong quarterly results, posting $2.28 in earnings per share versus the $1.79 consensus estimate and $481 million in revenue, up 47.7% year over year and well above expectations.
• Insiders have sold shares recently, including CEO Helen Torley’s $2.08 million sale, while institutional investors own a substantial 97.79% of outstanding shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $109.68 and last traded at $108.08, with a volume of 101370 shares. The stock had previously closed at $106.49.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HALO shares. TD Cowen increased their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a report on Friday, August 7th. Citigroup reiterated a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citizens Jmp raised their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. Finally, Morgan Stanley lowered their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 12th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Stock Up 1.3%

The business's 50 day simple moving average is $87.76 and its 200-day simple moving average is $74.93. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.24 billion, a price-to-earnings ratio of 32.19, a price-to-earnings-growth ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company's stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 42,478 shares of company stock valued at $3,767,304 in the last three months. Insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Empowered Funds LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $755,000. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at approximately $195,000. Hsbc Holdings PLC increased its position in Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock worth $522,000 after buying an additional 5,448 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock worth $577,000 after buying an additional 650 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source